Related references
Note: Only part of the references are listed.Single dose of anti-CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance
Virginia A. Pedicord et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate
Alexander J. Muller et al.
CANCER RESEARCH (2010)
Lck is a key target of imatinib and dasatinib in T-cell activation
K. C. Lee et al.
LEUKEMIA (2010)
ETV1 is a lineage survival factor that cooperates with KIT in gastrointestinal stromal tumours
Ping Chi et al.
NATURE (2010)
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
Gideon Bollag et al.
NATURE (2010)
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
Keith T. Flaherty et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Agonist Anti-GITR Monoclonal Antibody Induces Melanoma Tumor Immunity in Mice by Altering Regulatory T Cell Stability and Intra-Tumor Accumulation
Adam D. Cohen et al.
PLOS ONE (2010)
Inducing the tryptophan catabolic pathway, indoleamine 2,3-dioxygenase (IDO), for suppression of graft-versus-host disease (GVHD) lethality
Lisa K. Koch et al.
BLOOD (2009)
Natural Killer Cell IFN-γ Levels Predict Long-term Survival with Imatinib Mesylate Therapy in Gastrointestinal Stromal Tumor-Bearing Patients
Cedric Menard et al.
CANCER RESEARCH (2009)
OX40 engagement and chemotherapy combination provides potent antitumor immunity with concomitant regulatory T cell apoptosis
Daniel Hirschhorn-Cymerman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Tryptophan Deprivation Induces Inhibitory Receptors ILT3 and ILT4 on Dendritic Cells Favoring the Induction of Human CD4+CD25+ Foxp3+ T Regulatory Cells
Manuela Brenk et al.
JOURNAL OF IMMUNOLOGY (2009)
IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells
Babak Baban et al.
JOURNAL OF IMMUNOLOGY (2009)
Interferon-Dependent Engagement of Eukaryotic Initiation Factor 4B via S6 Kinase (S6K)-and Ribosomal Protein S6K-Mediated Signals
Barbara Kroczynska et al.
MOLECULAR AND CELLULAR BIOLOGY (2009)
Noninvasive Multimodality Imaging of the Tumor Microenvironment: Registered Dynamic Magnetic Resonance Imaging and Positron Emission Tomography Studies of a Preclinical Tumor Model of Tumor Hypoxia
HyungJoon Cho et al.
NEOPLASIA (2009)
Immune cells in primary gastrointestinal stromal tumors
Silke Cameron et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2008)
Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy
Karl S. Peggs et al.
IMMUNOLOGICAL REVIEWS (2008)
Indoleamine 2,3-dioxygenase in T-cell tolerance and tumoral immune escape
Jessica B. Katz et al.
IMMUNOLOGICAL REVIEWS (2008)
Cancer testis antigen expression in gastrointestinal stromal tumors: New markers for early recurrence
Daniel Perez et al.
INTERNATIONAL JOURNAL OF CANCER (2008)
Primary and Secondary Kinase Genotypes Correlate With the Biological and Clinical Activity of Sunitinib in Imatinib-Resistant Gastrointestinal Stromal Tumor
Michael C. Heinrich et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
Charles D. Blanke et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Imatinib Mesylate Inhibits CD4+CD25+ Regulatory T Cell Activity and Enhances Active Immunotherapy against BCR-ABL- Tumors
Nicolas Larmonier et al.
JOURNAL OF IMMUNOLOGY (2008)
Role of the At pathway in mRNA translation of interferon-stimulated genes
Surinder Kaur et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Immunological aspects of cancer chemotherapy
Laurence Zitvogel et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase
Madhav D. Sharma et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Gastrointestinal stromal tumour
Brian P. Rubin et al.
LANCET (2007)
Indoleamine 2,3-dioxygenase and tumor-induced tolerance
David H. Munn et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Rosmarinic acid inhibits indoleamine 2,3-dioxygenase expression in murine dendritic cells
Hwa Jung Lee et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy
Ursula Grohmann et al.
NATURE MEDICINE (2007)
Regulatory effects of mammalian target of rapamycin-activated pathways in type I and II interferon signaling
Surinder Kaur et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses
De-Yan Hou et al.
CANCER RESEARCH (2007)
Mad2 overexpression promotes aneuploidy and tumorigenesis in mice
Rocio Sotillo et al.
CANCER CELL (2007)
Somatic activation of KIT in distinct subtypes of melanoma
John A. Curtin et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Oncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumor
Ferdinand Rossi et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
CTLA4 blockade and GM-CSF combination immunotherapy alters the intratumor balance of effector and regulatory T cells
Sergio A. Quezada et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Regulatory T cells, tumour immunity and immunotherapy
WP Zou
NATURE REVIEWS IMMUNOLOGY (2006)
Prognostic value of indoleamine 2,3-dioxygenase expression in colorectal cancer:: Effect on tumor-infiltrating T cells
G Brandacher et al.
CLINICAL CANCER RESEARCH (2006)
Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer
E Sato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Differential regulation of the p70 S6 kinase pathway by interferon αt (IFNα) and imatinib mesylate (STI571) in chronic myelogenous leukemia cells
S Parmar et al.
BLOOD (2005)
Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells
A Okamoto et al.
CLINICAL CANCER RESEARCH (2005)
Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner
R Seggewiss et al.
BLOOD (2005)
IDO expression by dendritic cells: Tolerance and tryptophan catabolism
AL Mellor et al.
NATURE REVIEWS IMMUNOLOGY (2004)
Modulation of tryptophan catabolism by regulatory T cells
F Fallarino et al.
NATURE IMMUNOLOGY (2003)
Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase
C Uyttenhove et al.
NATURE MEDICINE (2003)
Gastrointestinal stromal tumors in a mouse model by targeted mutation of the Kit receptor tyrosine kinase
G Sommer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
PDGFRA activating mutations in gastrointestinal stromal tumors
MC Heinrich et al.
SCIENCE (2003)
Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
GD Demetri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Conventional and molecular cytogenetic characterization of a new human cell line, GIST-T1, established from gastrointestinal stromal tumor
T Taguchi et al.
LABORATORY INVESTIGATION (2002)
Share Paper
